A study to compare the effect of two blinded doses of Casodex [bicalutamide] (ICI 176,334 100 mg and 150mg daily) and castration [orchiectomy] in the treatment of advanced carcinoma of the prostate

Trial Profile

A study to compare the effect of two blinded doses of Casodex [bicalutamide] (ICI 176,334 100 mg and 150mg daily) and castration [orchiectomy] in the treatment of advanced carcinoma of the prostate

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 26 Nov 2005

At a glance

  • Drugs Bicalutamide (Primary)
  • Indications Prostate cancer
  • Focus Therapeutic Use
  • Sponsors AstraZeneca
  • Most Recent Events

    • 26 Nov 2005 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top